Corcellys Therapeutics develops regenerative cell therapies to restore the ocular surface and address severe corneal diseases with limited treatment options.
Our team. Building the Future of Cell Therapy
Corcellys Therapeutics is led by a multidisciplinary team with extensive international experience spanning regenerative medicine, pluripotent stem cell biology, translational development, CMC strategy, and GMP manufacturing of advanced therapy medicinal products (ATMPs).
Developing regenerative cell therapies to restore vision.
We combine stem cell biology, translational development, and deep cell therapy expertise to transform regenerative science into practical therapies for severe ocular diseases.
Transforming stem cell biology into regenerative therapies for the cornea
OUR TEAM
Bringing together deep expertise in stem cell biology, cell therapy development and translation to build regenerative therapies for the eye.
CARLOS VILLAESCUSA
Co-Founder | CEO & CSO
MICHAEL WAGNER CHRISTIANSEN
Co-Founder | CTO
DMITRY PENKOV
Senior Scientist
HUGO ÅKERSTRAND
Senior Scientist
Building the next generation of regenerative therapies for the eye
hUMAN STEM CELLS
TP63 / ZO1
Limbal stem cells
CEBPD / BMI1 / ZO1
limbal cell colony
scaling up
cryo cells
.png)
cell culture
bio materials
BUILT FOR TRANSLATION
Defined Limbal Stem Cell Identity
Defined Limbal Stem Cell Identity
High-Purity Cell Populations
High-Purity Cell Populations
Robust Cell Expansion
Robust Cell Expansion
Cryopreserved Product Format
Cryopreserved Product Format
High Post-Thaw Viability
High Post-Thaw Viability
Practical Surgical Delivery
Practical Surgical Delivery
Translational In Vivo Development
Translational In Vivo Development
Designed for Clinical Scalability
Designed for Clinical Scalability
DESIGNED FOR REAL-WORLD USE
Ready-to-Use Product Format
Ready-to-Use Product Format
Standardized Cryopreservation
Standardized Cryopreservation
Reliable Post-Thaw Recovery
Reliable Post-Thaw Recovery
Practical Clinical Handling
Practical Clinical Handling
Controlled Cell Delivery
Controlled Cell Delivery
Compatible with Surgical Workflows
Compatible with Surgical Workflows
Scalable Manufacturing Strategy
Scalable Manufacturing Strategy
Designed for Broad Patient Access
Designed for Broad Patient Access
Corcellys Therapeutics is developing investigational cell therapies that are currently in preclinical development. The safety and efficacy of these therapies have not been established, and they have not been approved for clinical use by any regulatory authority.
Information presented on this website is provided for scientific and informational purposes only and should not be interpreted as medical advice or as a representation of future clinical performance. Development plans, product characteristics and therapeutic approaches may evolve as research and development progresses.
Let´s Advance Regenerative Eye Therapies Together
We welcome conversations with investors, researchers, clinicians and partners who share our ambition to bring regenerative cell therapies to patients with severe ocular disease.
Science, Progress & Perspectives
Follow the latest from Corcellys Therapeutics, including scientific progress, company updates and perspectives on regenerative ophthalmology and cell therapy.
Questions About Our Science & Approach
What is Corcellys Therapeutics developing?
Corcellys Therapeutics is developing regenerative cell therapies for severe ocular diseases. Our lead program focuses on limbal stem cell deficiency (LSCD), a condition in which loss or dysfunction of limbal stem cells prevents normal regeneration of the corneal surface.
What is limbal stem cell deficiency?
Limbal stem cells continuously renew the corneal epithelium and help maintain a clear and healthy ocular surface. When these cells are lost or severely impaired, the cornea can become unstable and vascularized, resulting in chronic discomfort, impaired vision and, in severe cases, blindness.
How is the Corcellys approach different?
Our approach brings together stem cell biology, scalable manufacturing, cryopreservation and translational development. We are developing a robust, cryopreserved cell therapy intended to support practical clinical use and regeneration of a functional corneal surface.
Who could potentially benefit from this therapy?
Our lead program is being developed for patients with severe limbal stem cell deficiency. This includes patients for whom existing treatment options are limited, particularly when sufficient healthy limbal tissue is not available for an autologous treatment approach.
What stage of development is the program at?
Our lead program is in preclinical development. We are advancing the therapy through further product development and translational studies designed to support its progression toward future clinical evaluation.
Is Corcellys working only on the cornea?
The cornea is our initial focus, where our team has extensive experience in stem cell biology and translational development. Over time, we see opportunities to apply our expertise and regenerative medicine platform to additional serious ocular diseases.
What is Corcellys Therapeutics’ Privacy Policy?
Corcellys Therapeutics respects your privacy and processes personal information only when necessary for legitimate business purposes. If you contact us through this website, we may collect information you voluntarily provide, such as your name, email address, organization and message, for the purpose of responding to your inquiry and maintaining relevant business correspondence.
We do not sell personal information or use information submitted through our contact form for unrelated marketing purposes. Personal data is handled in accordance with applicable data protection legislation, including the EU General Data Protection Regulation (GDPR), and retained only for as long as reasonably necessary for the purpose for which it was collected or as required by law.
If you have questions regarding your personal data or wish to request access, correction or deletion, please contact Corcellys Therapeutics using the contact details provided on this website.
What are the Terms of Use for this website?
The content of this website is provided by Corcellys Therapeutics for general scientific, corporate and informational purposes only. While we aim to keep the information accurate and current, no guarantee is made regarding its completeness, accuracy or continued availability.
Information concerning research programs, technologies or potential therapeutic applications may describe investigational activities that remain under development and may change as research progresses. Nothing on this website constitutes medical advice, an offer to provide medical treatment, or a representation that any investigational therapy will ultimately receive regulatory approval or become commercially available.
Unless otherwise indicated, the content, text, graphics and other materials on this website are owned by or used with permission by Corcellys Therapeutics and may not be reproduced or used for commercial purposes without prior permission.